Auron Therapeutics
Series B in 2025
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.
Leyden Labs
Series B in 2025
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.
Nomad Health
Series E in 2024
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.
Sovato Health specializes in remote surgical access, offering a platform that connects skilled surgeons with patients in underserved areas. This platform integrates people, systems, tools, data, and business models to ensure safe, scalable, and sustainable remote surgical procedures.
Best Doctors
Venture Round in 2023
Best Doctors offers an innovative employee health benefit that provides access to global medical expertise for confident healthcare decisions. When facing significant medical choices, members can consult with leading specialists worldwide to ensure accurate diagnoses and appropriate treatments.
Tisento Therapeutics
Series A in 2023
Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.
Vytyl Health Management
Venture Round in 2023
Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.
Auron Therapeutics
Series A in 2022
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.
Nomad Health
Venture Round in 2022
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.
Foresight Mental Health
Series C in 2022
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.
Podimetrics
Series C in 2022
Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.
Nomad Health
Series D in 2021
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.
Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.
Auron Therapeutics
Seed Round in 2021
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.
Podimetrics
Series B in 2020
Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.
Foresight Mental Health
Series A in 2020
Foresight Mental Health is a technology-enabled psychiatry and therapy services company that directly employs psychiatrists, therapists, and psychiatric nurse practitioners to treat patients in its clinics. The company develops technology in collaboration with its providers, leveraging software and biomedical engineering to enhance care. Through a network of clinics, it offers a broad range of mental health treatments and wellness services and maintains patient profiles and a repository of scientific research and clinical information, including genetic profiles, comprehensive symptom profiles, and brain-chemical balance estimates to inform personalized care.
Iora Health
Series F in 2020
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Lyra Therapeutics
Series C in 2020
Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.
Podimetrics
Series B in 2019
Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.
Nomad Health
Series C in 2019
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.
Iora Health
Series E in 2018
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Nomad Health
Series B in 2018
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.
Iora Health
Series D in 2016
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Sofregen Medical
Series A in 2016
Founded in 2014, Sofregen Medical specializes in developing silk protein-based biomaterials for use in aesthetic procedures and surgeries. The company aims to enhance soft tissue regeneration, restoring function and cosmetic appearance for medical and aesthetic patients worldwide.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.
Navitor Pharmaceuticals
Series B in 2015
Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.
Iora Health
Series C in 2015
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Navitor Pharmaceuticals
Series A in 2014
Navitor Pharmaceuticals is a biopharmaceutical company developing targeted therapies for various diseases by modulating mTORC1 activity. Founded in 2009, the company is headquartered in Cambridge, Massachusetts.
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.
Iora Health
Series B in 2013
Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.
Fate Therapeutics
Series B in 2011
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.
Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.
Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.
Phytel
Venture Round in 2010
Phytel, Inc., founded in 1996 and based in Dallas, Texas, specializes in providing healthcare organizations with population health management software solutions. These solutions are designed to deliver coordinated care to patients by offering disease management and preventive care protocols that identify and notify non-compliant patients of needed healthcare actions. Phytel develops and maintains prescription, lab, and clinical data for effective health and disease management. The company also provides systems integration, application development, and reporting services. Phytel serves a variety of healthcare entities, including accountable care organizations, physician practices, hospitals, health systems, integrated delivery networks, community health centers, and consultants.
Fate Therapeutics
Series B in 2009
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.
Ironwood Pharmaceuticals
Venture Round in 2009
Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.
Pervasis Therapeutics
Series C in 2009
Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.
GI Dynamics
Series C in 2009
GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.
Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.
CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software products, including CodeAssist, which automates the coding process by integrating with user operational information systems, and CodeComplete, an outsourced coding solution. Additionally, CodeRyte's DataScout tool analyzes physician narratives to extract clinically relevant information from both free-text and structured medical records. By streamlining coding processes and improving data extraction, CodeRyte enables healthcare providers to secure appropriate reimbursements, enhance compliance, and make informed treatment and business decisions. Its solutions are utilized by many prominent physician practices, billing companies, and academic medical centers across the nation, positioning CodeRyte as a vital component of their coding and data-mining operations.
Imprivata
Series C in 2008
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.
Pervasis Therapeutics
Venture Round in 2008
Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.
Cardiac Dimensions
Series D in 2007
Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.
Fate Therapeutics
Series A in 2007
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders. The company specializes in NK- and T-cell immuno-oncology programs, with a diverse pipeline that includes candidates such as FT516 and FT596 for treating various hematologic malignancies, FT538 for acute myeloid leukemia and multiple myeloma, and FT500 for advanced solid tumors. Fate Therapeutics employs advanced techniques involving induced pluripotent stem cells (iPSCs) to create engineered product candidates, which are designed to be off-the-shelf solutions. The company has established strategic collaborations with notable partners, including Ono Pharmaceutical Co. Ltd. and Janssen Biotech, to enhance its research and development capabilities. Founded in 2007, Fate Therapeutics aims to leverage cutting-edge science to create innovative therapies that restore health by modulating the properties of stem cells.
Phreesia is a technology company focused on enhancing patient care experiences. It replaces traditional clipboard-based check-in processes with secure, wireless touchscreen devices that collect patient information compatible with electronic medical records. Phreesia improves operational efficiency and patient satisfaction by automating administrative tasks, providing relevant health education, and facilitating seamless data transfer between patients' previous visits.
Ascend Health
Series B in 2007
Ascend Health Corporation is a healthcare provider specialising in behavioural health. It operates inpatient and day hospital facilities offering personalised care for children, adolescents, adults, and seniors. Ascend focuses on integrating its services with local community healthcare systems to deliver high-quality mental health and chemical dependency treatments.
CodeRyte is a leading provider of computer-assisted coding and clinical data extraction solutions tailored for the healthcare industry. The company offers advanced software products, including CodeAssist, which automates the coding process by integrating with user operational information systems, and CodeComplete, an outsourced coding solution. Additionally, CodeRyte's DataScout tool analyzes physician narratives to extract clinically relevant information from both free-text and structured medical records. By streamlining coding processes and improving data extraction, CodeRyte enables healthcare providers to secure appropriate reimbursements, enhance compliance, and make informed treatment and business decisions. Its solutions are utilized by many prominent physician practices, billing companies, and academic medical centers across the nation, positioning CodeRyte as a vital component of their coding and data-mining operations.
Imprivata
Series B in 2006
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.
Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.
Pervasis Therapeutics
Series B in 2005
Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.
Imprivata
Series A in 2005
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.
Pervasis Therapeutics
Series A in 2004
Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.
GI Dynamics
Series B in 2004
GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.
Cardiac Dimensions
Series C in 2004
Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.
Pervasis Therapeutics
Seed Round in 2004
Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.
The Center from Health Promotion
Venture Round in 2003
The Center for Health Promotion Inc. delivers tobacco cessation and weight
management services to customers nationwide. As an operating unit of Group
Health Cooperative (Seattle) for almost 20 years, CHP developed the
telephone-based Free & Clear program and established itself a national leader
in tobacco cessation.
Today CHP continues to deliver tobacco cessation services through health
plans, businesses and labor organizations around the country. CHP also
provides phone-based tobacco cessation services to residents of Georgia,
Maine, Minnesota, Oklahoma, Oregon, Utah, Washington and Wisconsin through
contracts with state agencies or coalitions. The company is actively engaged
in research trials with major research centers including The Stanford Research
Institute in Menlo Park, Calif., the Center for Health Research in Portland,
Ore., and the Fred Hutchison Cancer Research Center and Group Health's Center
for Health Studies, both in Seattle. This active research is undertaken to
help improve CHP's services to smokers and increase scientific understanding
of this key health issue.
Alnylam Pharmaceuticals
Venture Round in 2003
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.
GI Dynamics
Series A in 2003
GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.
Cardiac Dimensions
Series B in 2002
Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.
Imprivata
Series A in 2002
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.
Accordant Health Services
Venture Round in 2000
Accordant provides its program members with healthcare advice.
The service focuses on delivering support for patients with rare, chronic diseases. Its care management solutions comprise of tools and resources of professionals in the healthcare sector. The service also delivers care management services for rare diseases which include health plans, employers, and third party administrators.
Accordant is a subsidiary of CVS Caremark. It was founded by Steve Schelhammer and is headquartered in Greensboro, North Carolina.
Data Sciences International
Venture Round in 1997
Founded in 1984, Data Sciences International specializes in biomedical research with a focus on systems physiology and pharmacology. The company provides telemetry devices, instrumentation, software, and services for physiological monitoring, serving various industries including pharmaceuticals, academia, government, and biotechnology. Its product portfolio includes implantable telemetry transmitters, external telemetry devices, signal conditioners, glucose monitoring solutions, infusion pumps, and data services.